ZhuZhou QianJin Pharmaceutical Co.,Ltd

600479

CNE000001GX3

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
11.55 ^CNY	+1.67%		+1.85%	+7.24%

Apr. 29	ZhuZhou QianJin Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Jan. 24	Qianjin Pharma Unit Gets Nod for Supplemental New Drug Application for Teralithe Biosimilar	MT

Hunan Xinhexin Bio-Pharmaceutical Co., Ltd. announced that it expects to receive CNY 310 million in funding from ZhuZhou QianJin Pharmaceutical Co.,Ltd, Capstone Strategic, Inc.

December 05, 2023

Hunan Xinhexin Bio-Pharmaceutical Co., Ltd. announced that it will receive CNY 310,000,000 equity round of funding on December 6, 2023. The transaction include the participation new investors, Anhua Huangyuan Tea Tourism Industry Poverty Alleviation Development Co., Ltd., Wuxi AstraZeneca Zhongjin No. 1 Venture Capital Partnership Enterprise (Limited Partnership), ZhuZhou QianJin Pharmaceutical Co., Ltd., Changde Jinxin No.

2 Medical Instruments Industry Investment Enterprise (Limited Partnership), Changde Modern Agriculture Industry Investment Fund Enterprise (Limited Partnership), Changde Xingxin Industry Development Investment Fund Partnership Enterprise (Limited Partnership), Changde Xingxiang Jintou Industrial Growth Investment Fund Partnership Enterprise (Limited Partnership), Taicang Kaihui Growth No. 2 Investment Fund Partnership Enterprise (Limited Partnership) and returning investors Capstone Strategic, Inc.,ZhuZhou QianJin Pharmaceutical Co.,Ltd. The company's registered capital is subscribed by CNY 5,620,884.

Latest news about ZhuZhou QianJin Pharmaceutical Co.,Ltd

ZhuZhou QianJin Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Qianjin Pharma Unit Gets Nod for Supplemental New Drug Application for Teralithe Biosimilar	Jan. 24	MT
ZhuZhou QianJin Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Jan. 18	CI
Hunan Xinhexin Bio-Pharmaceutical Co., Ltd. announced that it has received CNY 50 million in funding from a group of investors	Dec. 20	CI
Hunan Xinhexin Bio-Pharmaceutical Co., Ltd. announces tranche update	Dec. 16	CI
Hunan Xinhexin Bio-Pharmaceutical Co., Ltd. announced that it expects to receive CNY 310 million in funding from ZhuZhou QianJin Pharmaceutical Co.,Ltd, Capstone Strategic, Inc.	Dec. 05	CI
ZhuZhou QianJin Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Hunan Xinhexin Bio-Pharmaceutical Co., Ltd. announced that it expects to receive CNY 500 million in funding from ZhuZhou QianJin Pharmaceutical Co.,Ltd	23-10-17	CI
ZhuZhou QianJin Pharma Gets Nod to Register Blood Circulation Drug in Canada	23-10-10	MT
QianJin Pharma’s Product Selected Among Top 100 Evidenced-Based Traditional Chinese Medicines	23-09-08	MT
ZhuZhou QianJin Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
ZhuZhou QianJin Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
ZhuZhou QianJin Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-12	CI
Zhuzhou Qianjin Pharma's Unit Gets Nod for Chronic Hepatitis B Drug	23-04-10	MT
ZhuZhou QianJin Pharma Promotes Vice Chairman to Chairman	23-03-17	MT
Zhuzhou QianJin Pharmaceutical's Chairman Resigns; Shares Rose 5%	23-03-15	MT
ZhuZhou QianJin Pharma Appoints Vice Chairman	22-12-20	MT
ZhuZhou QianJin Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
ZhuZhou QianJin Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
ZhuZhou QianJin Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
ZhuZhou QianJin Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-01-14	CI
ZhuZhou QianJin Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Zhuzhou Qianjin Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-26	CI
Zhuzhou Qianjin Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-28	CI
Zhuzhou Qianjin Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-14	CI

Chart ZhuZhou QianJin Pharmaceutical Co.,Ltd

Duration

Period

Chart ZhuZhou QianJin Pharmaceutical Co.,Ltd

More charts

Company Profile

ZhuZhou QianJin Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production, wholesaling and retailing of drugs. The Company's main products include tablets, granules, pills, hard capsules, syrups, herbs, vinum and gels, among others. The company is also involved in the businesses of cultural entertainment, logistics and distribution, as well as the provision of hygienic products.

Sector

Pharmaceuticals

Calendar

2024-05-20 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHUZHOU QIANJIN PHARMACEUTICAL CO.,LTD	+7.24%	685M
NOVO NORDISK A/S	+21.85%	546B
JOHNSON & JOHNSON	-4.77%	359B
MERCK & CO., INC.	+16.97%	323B
ABBVIE INC.	+5.69%	290B
ASTRAZENECA PLC	+13.68%	234B
NOVARTIS AG	+3.65%	198B
ROCHE HOLDING AG	-11.12%	194B
AMGEN INC.	+8.08%	167B
PFIZER, INC.	-3.40%	157B